Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight [Yahoo...
Zai Lab Limited - American Depositary Shares (ZLAB)
US:NASDAQ Investor Relations:
zailaboratory.com/about/investors.php
Company Research
Source: Yahoo! Finance
The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic capabilities. Advancements in targeted therapies and immunotherapies are expanding treatment options and boosting market demand. Additionally, ongoing clinical research of therapies such as obrixtamig (BI 764532) (Boehringer Ingelheim and Oxford BioTherapeutics), gocatamig (MK-6070) (Merck and Daiichi Sankyo), ZL-1310 (Zai Lab and MediLink Therapeutics), peluntamig (PT217) (Phanes Therapeutics), and others and investment from pharmaceutical developers are expected to further accelerate market expansion in the coming years. LAS VEGAS March 9, 2026 /PRNewswire/ -- Recently published Neuroendocrine Carcinoma Market Insights report includes a comprehensive understanding of current treatment practices, neuroendocrine carcinoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading mar
Show less
Read more
Impact Snapshot
Event Time:
ZLAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZLAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZLAB alerts
High impacting Zai Lab Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ZLAB
News
- Zai Lab (ZLAB) had its price target lowered by JPMorgan Chase & Co. from $39.00 to $32.00. They now have an "overweight" rating on the stock.MarketBeat
- Nationwide International Small Cap Fund Q4 2025 Commentary [Seeking Alpha]Seeking Alpha
- Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC) [Yahoo! Finance]Yahoo! Finance
- Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)Business Wire
- Is Zai Lab (ZLAB) Now A Bargain After Recent 15.8% Share Price Jump? [Yahoo! Finance]Yahoo! Finance
ZLAB
Earnings
- 2/26/26 - Miss
ZLAB
Sec Filings
- 3/19/26 - Form 4
- 3/16/26 - Form 4
- 3/16/26 - Form 4
- ZLAB's page on the SEC website